Surface the 1-3 things that matter today.
From a chart of 8+ findings, the platform pulls forward what's tied to today's appointment and collapses the rest behind a clean expander.
A clinical decision support surface that lives where you already practice. Genomic, lab, medication, wearable, and EHR signals — distilled into the small set of decisions that actually move care today.
Skip the feature lists. This is what the platform is actually trying to do for you between 09:30 and 09:42.
From a chart of 8+ findings, the platform pulls forward what's tied to today's appointment and collapses the rest behind a clean expander.
CPIC level, PharmGKB, USPSTF, ADA, AHA, FDA label — with a versioned rule ID you can point to in a chart note or a deposition.
Built-in interaction checker fires before any PGx surface — no separate Lexicomp tab, no swivel-chair into another system.
Co-sign on prescribing-relevant accepts. Suppression with rationale. Amendment lineage. The clinician is always the final mover.
Switch the lane and the default panels, rule subsets, and report templates reshape themselves. A psychiatrist and a cardiometabolic specialist see different surfaces from identical underlying data.
Polypharmacy reviews, preventive screening, age-banded panels, longitudinal HbA1c / lipid / renal.
ApoB · Lp(a) · LDL · HbA1c trends with statin tolerability + PGx-aware therapy review.
CYP2D6 / CYP2C19-aware SSRI / SNRI review with PHQ-9 / GAD-7 trends and adherence overlay.
Metabolic panels, glucose / CGM context, insulin and incretin therapy review.
ApoB, Lp(a), inflammation, body-comp, sleep, HRV, recovery — with curated supplements + Rx context.
Pharmacist-led PGx and polypharmacy review with co-sign and EHR-paste handoff.
Structured patient data in.
Evidence-linked recommendations out.
Licensed clinician at every gate.
PrecisionRx AI is intended to provide AI-driven clinical decision support to licensed clinicians by analyzing structured patient-specific data and generating personalized, evidence-linked recommendations for clinician review. The product does not diagnose, prescribe, or replace clinical judgment.
Adoption fails when CDS is loud, slow, or detached from the order flow. We've sized the product against those three failure modes.
Jane Smith, 38F. CYP2C19 PM on sertraline. New atorvastatin + clarithromycin clash. Three things to address today, eight more in the chart for context. No demo call required.